CISEN(SH:603367) Zheng Quan Zhi Xing·2025-05-12 08:28Core Viewpoint - The company held a performance briefing for the fiscal year 2024 and the first quarter of 2025, focusing on cash dividends and engaging with investors through an interactive online format [1][2]. Group 1: Performance Briefing Details - The performance briefing took place on May 12, 2025, from 9:00 to 10:00 AM at the Shanghai Stock Exchange Roadshow Center [1]. - The company announced a cash dividend distribution plan, proposing a total cash dividend of 0.44 yuan per share (including tax) for 2024, with 0.22 yuan already distributed for the first half of the year [3]. Group 2: Investor Interaction and Company Responses - The company emphasized its strong service innovation capabilities, providing personalized supply chain services and enhancing market product marketing [2]. - The core management team has significant experience and established effective management mechanisms to improve production efficiency and innovation [2]. - The company has a clear research and development advantage, focusing on multiple key therapeutic areas and accelerating the development of differentiated products [2]. - The company maintains a comprehensive product quality management system, prioritizing quality and safety in its pharmaceutical offerings [2]. - The product portfolio covers over ten therapeutic areas, including chronic diseases, infections, cardiovascular issues, tumors, digestive system diseases, and rare diseases, addressing diverse patient needs [2]. Group 3: Industry Context - The pharmaceutical industry is a crucial part of the national economy, characterized by weak cyclicality, high investment, high risk, high technical barriers, and strict regulation [4]. - The industry has experienced rapid growth due to rising healthcare demands driven by economic growth, increasing living standards, and an aging population [4]. - The industry is undergoing a transformation towards high-quality development, with increased concentration and accelerated resource integration, while facing challenges such as policy adjustments and intensified competition [4].